Natesto Testosterone Nasal Gel for Hypogonadal Men

Erectile Dysfunction Clinical Trial

Official title:

Placebo-Controlled Cross-Over Pilot Trial of Natesto Testosterone Nasal Gel on Demand for Hypogonadal Men With Sexual Dysfunction Using Daily Phosphodiesterase-5 Inhibitor

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05484167
• Other study ID #: 00144770
• Status: Withdrawn
• Phase: Phase 4
• Start date: January 1, 2023
• Est. completion date: April 1, 2025

Study information

• Verified date: December 2022
• Source: University of Utah
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine if testosterone deficient men who are using daily Tadalafil (a phosphodiesterase-5 Inhibitor), will have a significant improvement in erectile function and satisfaction with erectile dysfunction treatment when using on-demand Testosterone Nasal Gel (TNG) prior to sexual activity compared to placebo.

Description:

The purpose of this study is to determine if testosterone deficient men whose primary symptom is erectile dysfunction, who are using daily Tadalafil (a phosphodiesterase-5 Inhibitor), will have a significant improvement in erectile function and satisfaction with erectile dysfunction treatment when using on-demand Testosterone Nasal Gel (TNG) prior to sexual activity compared to placebo.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 1, 2025
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Ability to understand and provide written informed consent for the study.
• Ability to read and complete electronic questionnaires in English.
• Adult males between the ages of 18-64 years
• Mild-moderate ED based on SHIM score between 8-21 at study entry
• Ability to take daily Tadalafil
• Ability to undergo venipuncture
• Ability to provide ejaculated semen sample
• Stable female sexual partner with sexual activity at least 1-3 times/month
• Hypogonadism defined as two (one done as SOC within the last 6 months and one done at the time of screening) early morning total testosterone lab values <300

Exclusion Criteria:

• Morbid Obesity - BMI >35
• History of Diabetes (HBA1c >6.0)
• Hematocrit < 35% or > 54% at study entry
• Concurrent or Prior use of other exogenous testosterone or hormone therapy (SERM, aromatase inhibitor, gonadotropins) within the last 3 months.
• Concurrent use of other prescription medications for ED including PDE5 inhibitors, intracavernosal injection therapy, urethral suppositories
• Concurrent use of nitrates in any form
• History of pelvic radiation
• Spinal cord injury
• Any progressive neurologic disease (Alzheimer's, Parkinson's, multiple sclerosis, etc).
• History of penile prosthesis
• History of prostatectomy
• History of transurethral resection of prostate
• History of stroke or myocardial infarction within the past 6 months
• History of congestive heart failure
• History of untreated obstructive sleep apnea
• History of liver disease (Serum transaminases > 2.5 times upper limit of normal)
• History of chronic kidney disease (GFR<60 or Serum Cr >2)
• History of, current or suspected, prostate (abnormal DRE or elevated PSA >4.0) or breast cancer.
• History of azoospermia or oligospermia (<15 million/ml)
• History of vasectomy
• History of Priapism
• History of Polycythemia Vera
• Receipt of any investigational product within 4 weeks of study enrollment
• Recurrent upper respiratory or sinus infection (>3 times/month for >6 months)
• Recurrent epistaxis (>3 times/month for >6 months)

Related Conditions & MeSH terms

• Erectile Dysfunction
• Sexual Dysfunction

Intervention

Drug:
• Natesto Nasal Product
Nasal Gel used for 90 days then crossed over to placebo gel
• Placebo
A nasal gel with no active ingredients

Locations

Country	Name	City	State
United States	University of Utah, Division of Urology	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
University of Utah	Acerus Pharmaceuticals Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of Erectile Function and Sexual Intercourse Satisfaction Total Scores Recorded at Baseline and End of Study.	The primary endpoint of the study will be mean change in erectile function and satisfaction with sexual intercourse using the validated SHIM questionnaire. This questionnaire has been used extensively in clinical trials evaluating PDE5i for ED and is also used very commonly in the clinical practice. The SHIM Is a 5 item questionnaire that assesses the ability to get and maintain an erection sufficient for intercourse (Q1-Q4) and Q5 which assesses patient satisfaction. Each question is scored 0 to 5 with a total maximum score of 25.; The investigators will look at the answers to all 5 questions and a higher score is interpreted as a better outcome.	At Baseline and at the end of the study (Day 180)
Secondary	Comparison of Sexual Function Scores Recorded at Baseline and End of Study	Secondary outcomes will include a comparison of answers to question #2 in the Sexual Encounter Profile (SEP): Was the participant able to insert the penis into the partner's vagina? This is a question asked at baseline and at the end of the study. Answers are recorded as Yes or No and Yes is interpreted as a better outcome.	At Baseline and at the end of the study (Day 180)
Secondary	Comparison of Erection Success Recorded at Baseline and End of Study	Secondary outcomes will include a comparison of answers to question #3 in the Sexual Encounter Profile (SEP): Did the participant's erection last long enough to have successful intercourse? This is a question that will be asked at baseline and at the end of the study. Answers are recorded as Yes or No and Yes is interpreted as a better outcome.	At Baseline and at the end of the study (Day 180)
Secondary	Comparison of Treatment Satisfaction Total Scores at Baseline and End of Study	Secondary outcomes will include a comparison of the total score for the Treatment Satisfaction Questionnaire for Medication (TSQM-9) at baseline and again at the end of the study.; The TSQM-9 scale is descriptive in nature and includes the following scales such as: Very satisfied; Somewhat satisfied; Neither satisfied nor dissatisfied; Somewhat dissatisfied; Very dissatisfied; Higher scores are considered as a better outcome.	At Baseline and at the end of the study (Day 180)
Secondary	Comparison of Erectile Dysfunction Inventory of Treatment Satisfaction Total Scores at Baseline and End of Study	Secondary outcomes will include a comparison of the total score for the Change in Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) at baseline and again at the end of the study. The EDITS scale is descriptive in nature and includes the following scales such as: Very satisfied; Somewhat satisfied; Neither satisfied nor dissatisfied; Somewhat dissatisfied; Very dissatisfied; Higher scores are considered as a better outcome.	Baseline and at the end of the study (Day 180)